Most Common Side Effects of Polivy
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab to treat relapsed or refractory diffuse large B-cell lymphoma, has these most frequently reported side effects from clinical trials and post-marketing data. In the pivotal GO29365 trial, neutropenia (41%), thrombocytopenia (39%), anemia (32%), fatigue (28%), diarrhea (25%), and peripheral neuropathy (23%) topped the list.[1][2]
Patients often experience infections like pneumonia (17%) and febrile neutropenia (15%), plus gastrointestinal issues such as nausea (21%) and constipation (18%).[1]
Why These Side Effects Occur
Polivy is an antibody-drug conjugate targeting CD79b on B-cells, delivering chemotherapy (monomethyl auristatin E) that disrupts microtubules. This causes cytopenias (low blood cells) from bone marrow suppression and neuropathy from axonal damage. Infusion reactions (13%) stem from the antibody component.[2][3]
Severe or Less Common Side Effects Patients Search For
Serious risks include:
- Progressive multifocal leukoencephalopathy (PML, rare but fatal brain infection).
- Tumor lysis syndrome.
- Hepatotoxicity (liver enzyme elevation in 10-15%).
- Cardiac issues like arrhythmias (5-10%).
Discontinuation due to adverse events occurred in 18% of trial patients.[1][2]
How Side Effects Compare to Rituxan + Bendamustine Alone
In the GO29365 trial, Polivy added significantly higher rates of grade 3-4 neutropenia (42% vs 11%) and peripheral neuropathy (40% vs 2%) compared to bendamustine-rituximab alone, but improved survival (median 12.4 vs 9.5 months).[1][4]
| Side Effect | Polivy Combo (%) | BR Alone (%) |
|-------------|-----------------|--------------|
| Neutropenia (grade 3-4) | 42 | 11 |
| Thrombocytopenia (grade 3-4) | 29 | 13 |
| Peripheral Neuropathy (any grade) | 40 | 2 |
| Fatigue (any grade) | 28 | 18 |
Managing Side Effects and Patient Tips
Neutropenia is managed with growth factors like Neulasta; neuropathy with dose reductions (seen in 10%). Monitoring includes weekly blood counts initially. Patients report neuropathy persisting months post-treatment, affecting 7% long-term.[2][5]
Who Reports These Most and When
Hematologic effects peak in cycles 1-2; neuropathy accumulates over 6+ cycles. Elderly patients (>65) face higher rates (50%+ cytopenias).[1]
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: FDA Label for Polivy
[3]: GO29365 Trial (NEJM, 2019)
[4]: Polivy HCP Site
[5]: Drugs.com Side Effects